Physician profile
Gregory A Hill
NPI 1700814225
$4,081.81
in general payments reported to CMS, 2019-2025
21 companies · $951 in 2025
The $951 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $191 · 2021: $222 · 2022: $474 · 2023: $816 · 2024: $785 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,577.87 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Abbvie INC. | $319.01 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $291.91 | 2019-2022 | |
| Ocular Therapeutix, INC. | $160.55 | 2022-2023 | Dextenza |
| Depuy Synthes Sales INC. | $146.09 | 2024 | Na, N/A, Foot Osteotomy Wedge System |
| Rxsight INC | $131.11 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Medtronic, INC. | $98.83 | 2021 | |
| Oyster Point Pharma, INC. | $49.89 | 2024 | Tyrvaya |
| Harrow Eye, LLC | $42.32 | 2023 | Iheezo |
| New World Medical,INC. | $36.28 | 2022-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Thea Pharma INC. | $33.14 | 2023 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $28.12 | 2023 | Cequa |
| Dompe US, INC. | $25.90 | 2024 | Oxervate |
| Biotissue Holdings INC. | $22.95 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $19.41 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $17.90 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.50 | 2022 | |
| Shire North American Group INC | $16.81 | 2019 | |
| Bausch & Lomb Americas INC. | $15.56 | 2023 | Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.